Percent of all patients

- Hypoglycaemia: 3.5%
- Weight gain: 14.8%
- Adverse events: 6.1%
- Blood sugar targets are not met: 86.9%
- Other reasons (not specified): 11.7%

Percent of all patients

- Metformin: 84.0% (Baseline), 84.5% (after therapy change)
- Sulfonylureas: 28.9% (Baseline), 26.3% (after therapy change)
- Glucosidase inhibitors: 2.7% (Baseline), 2.3% (after therapy change)
- Glinides: 4.5% (Baseline), 6.0% (after therapy change)
- Glitazones: 6.3% (Baseline), 10.3% (after therapy change)
- DPP-4 inhibitors: 4.9% (Baseline), 38.8% (after therapy change)
- GLP-1 analogues: 9.2%
- Short acting insulins: 2.7%
- Long acting insulins: 8.6%
- Short + long acting insulins: 3.9%
- Mixed insulins: 2.1%

17.3% on insulin